Investors Alert: Aratana Therapeutics, Inc. (NASDAQ:PETX), Neuralstem, Inc. (NYSEMKT:CUR), CTC Media, Inc (NASDAQ:CTCM), Unum Group (NYSE:UNM), Reed Elsevier NV (NYSE:ENL)

Aratana Therapeutics, Inc. (NASDAQ:PETX) belongs to Healthcare sector. Its weekly performance is 10.30%. On last trading day company shares ended up $15.63. Aratana Therapeutics, Inc. (NASDAQ:PETX) distance from 50-day simple moving average (SMA50) is 12.41%. Zacks cut shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) from a buy rating to a hold rating in a research note issued to investors on Wednesday.

Neuralstem, Inc. (NYSEMKT:CUR) shares moved down -0.59% in last trading session and ended the day at $1.69. CUR return on assets is -71.50%. Neuralstem, Inc. (NYSEMKT:CUR) quarterly performance is -12.89%. Neuralstem, Inc. (NYSEMKT:CUR) announced that it has been approved for listing on the NASDAQ Capital Market under the symbol “CUR.” The Company’s common stock will continue to trade on the NYSE MKT until the market close on July 10, 2015. Trading on the NASDAQ Capital Market is expected to commence on July 13, 2015.

On 10 July, CTC Media, Inc (NASDAQ:CTCM) shares advanced 1.06% and was closed at $1.91. CTCM EPS growth in last 5 year was 1.50%. CTC Media, Inc (NASDAQ:CTCM) year to date (YTD) performance is -58.94%. CTC Media, Inc (NASDAQ:CTCM) announced developments in connection with its response to the amendment to the Russian law “On Mass Media”, which will impose further restrictions on non-Russian ownership of Russian television companies beginning January 1, 2016.

Unum Group (NYSE:UNM) ended the last trading day at $35.86. Company weekly volatility is calculated as 1.58% and price to cash ratio as 106.39. Unum Group (NYSE:UNM) showed a weekly performance of -0.44%. Unum Group (NYSE:UNM) will release its second quarter results on Wednesday, July 29, at approximately 4 p.m. Eastern.

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) ended the last trading day at $1.29. Company weekly volatility is calculated as 3.56% and price to cash ratio as 4.50. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) showed a weekly performance of -0.77. On 25 June, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that the European Patent Office (EPO) has granted Patent Number 2,269,656, titled “Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer”. This important patent covers bavituximab as a composition of matter and for use in treating cancer including in combination with radiotherapy or chemotherapy, such as with docetaxel.

Leave a Reply

Your email address will not be published. Required fields are marked *